Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDE | P14735 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL13272362 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL10047687 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8763 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL14489489 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16897730 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL5690544 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158177-B2 | Delivery of active agents using a chocolate vehicle | DELAVAU LLC (US) | 2012-04-17 | — | — | US | claimed |
| US-20110177010-A1 | Vitamin preparation | NUTRI TEAM GMBH | 2011-07-21 | — | — | US | claimed |
| US-20110038988-A1 | Delivery of Active Agents Using a Chocolate Vehicle | DELAVAU LLC (US) | 2011-02-17 | — | — | US | claimed |
| US-20120101304-A1 | CELLS AND METHOD FOR PRODUCING ACETONE | EVONIK DEGUSSA GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-8158177-B2 | Delivery of active agents using a chocolate vehicle | DELAVAU LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120088313-A1 | METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE | JAPAN TOBACCO INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120082761-A1 | Delivery of Active Agents Using a Chocolate Vehicle | DELAVAU LLC (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| US-20120064543-A1 | METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE | VIRUS IKAGAKU KENKYUSHO INC. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8133523-B2 | Delivery of active agents using a chocolate vehicle | DELAVAU LLC (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2416158-A1 | METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE | Japan Tobacco, Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110070605-A1 | REVERSIBLE MHC MULTIMER STAINING FOR FUNCTIONAL PURIFICATION OF ANTIGEN-SPECIFIC T CELLS | IBA LIFESCIENCES GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-7906624-B2 | Use delivering a drug, a toxin, a nucleic acid molecule, a radionuclide or a detectable compound to a cell; exocyclic peptide containing a small protein construct designed to replace an antibody and further including a motif which facilitates formation of multimers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-15 | — | — | US | disclosed |
| WO-2011026606-A2 | COMPOSITIONS FOR THE TREATMENT OF HEMORRHOIDS AND RELATED DISEASES | BIONAP SRL (IT) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053224-A1 | NOVEL COMPOSITION OF MATTER AND METHOD FOR STIMULATING THE GROWTH OF BENEFICIAL MICROORGANISMS | NEWAGRICULTURE, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2011022838-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2011-03-03 | — | — | WO | disclosed |
| US-7897369-B2 | Isoprenoid wax ester synthases, isoprenoid acyl CoA-synthetases, and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110038988-A1 | Delivery of Active Agents Using a Chocolate Vehicle | DELAVAU LLC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110033579-A1 | Delivery of Active Agents Using a Chocolate Vehicle | DELAVAU LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110033578-A1 | Delivery of Active Agents Using a Chocolate Vehicle | DELAVAU LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TDP1 3949/4885MEN1 4671/4885ABL1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.